Three layers. Two engines. One thesis. Peptidal is an AI driven investment vehicle built around one conviction: the peptide value chain will absorb the largest share of pharmaceutical revenue growth this decade, and capital has only just begun to follow.
Most investors trade peptides through Lilly and Novo at the top of the chain. They miss the manufacturers running at capacity behind them, and the consumer brands selling the prescriptions out the front. Three layers, one demand curve.
Lilly and Novo are doing roughly $50B in combined GLP-1 sales. Behind them, thirty plus mid and small caps are running peptide programs across metabolic, cardiometabolic and obesity adjacent indications.
Bachem moved peptide API production from kilos to multi tonne territory. CordenPharma committed $981M of expansion. Novo paid $11B for Catalent's fill-finish lines outright. The bottleneck is priced, the build out is documented.
Hims hit a $10B+ market cap on GLP-1 compounding revenue, then halved on a single FDA shortage list shift. Now pivoting into branded LLY and NVO partnerships. The volatility is the trade.
Not a forecast. The capital flow, the manufacturing constraint and the consumer revenue are printing right now. The mispricing is in how concentrated equity coverage of it remains.
A liquid trading sleeve, a private ventures sleeve, and a single operating subsidiary. All three deployed in parallel inside one Australian wholesale unit trust. Full structural detail in the Information Memorandum.
One signal infrastructure, two products. A multi catalyst peptide bot covering the whole value chain, and Tretidal, the live single catalyst sub strategy. Same engine, different mandates.
The broader peptide bot. Long and short across the entire value chain. Catalysts on the drugs, capacity signal on the manufacturers, prescription momentum on the consumer names.
The original. Concentrated catalyst aware sub strategy on Lilly across the retatrutide sequence. Available as a focused product for investors who want the concentrated exposure.
The peptide value chain offers a stacked sequence of catalysts across all three layers. The bot trades the calendar, ventures positions ahead of it.
Selective positions in companies the bot can't reach because they aren't listed. Capped at roughly 25% of fund capital and side pocketed inside the trust so the liquid engine drives quarterly performance.
Co investment alongside established biotech VCs in Phase 2 and 3 metabolic and cardiometabolic peptide assets approaching IPO.
Early equity in oral peptide platforms, depot formulations, and selective CDMO capacity expansion plays.
Private positions in peptide and longevity DTC companies not yet listed. Superpower, Mochi, Ro, Henry, Eden tracked.
Sell side analysts, business press, regulators, operators, creators and clinicians are all converging from different angles. A curated sample.
Independent creators, clinicians and finance commentators on the peptide thesis. Tap to play.
Australian wholesale unit trust open to s708 sophisticated investors only. Liquid sleeve, side pocketed ventures sleeve, operating subsidiary held inside the trust. Full structural detail in the Information Memorandum.
Peptidal isn't macro diversified. If GLP-1 demand softens or a class wide safety signal materially changes the prescribing picture, all three layers move together. That correlation is the point. Investors looking for high conviction, multi mechanism exposure to the peptide value chain are the audience this vehicle is built for.
Peptidal is currently in formation. We are speaking with prospective cornerstone investors, family offices and wholesale allocators ahead of first close.
Qualified wholesale enquiries receive the Information Memorandum, the Peptidal universe and methodology overview, and a scheduled briefing with the founding team.
Your enquiry has been received. A member of the Peptidal team will respond within 48 hours with next steps and the Information Memorandum under NDA.
The following disclaimers form part of the information presented on this website. By continuing to view this website, you confirm that you have read, understood and accepted these terms. Click any heading to expand.